杰富瑞集团分析师Andrew Tsai表示，莫德纳（Moderna）在皮肤癌疫苗上的突破使这家制药商有望在2027-28年前拥有七款以上上市产品。该分析师表示，公司正将其产品组合多元化，覆盖呼吸系统、癌症治疗和AI设计的药物。公司2026年营收可能在2025年19亿美元的基础上增长至多10%，使其有望在2028年实现盈亏平衡。莫德纳实验性mRNA癌症疫苗的试验成功可能推动从2027年开始的销售增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.